---
author: Harvey Guo
created: 2024-03-11 14:49
modified: 2024-03-11 14:49
aliases:
  - Paget disease of the breast
share: true
---
![[Pasted image 20241018091605.png|Pasted image 20241018091605.png]]
# Epidemiology
---


# Etiology
---


# Benign cancer
---
## [[Intraductal papilloma|Intraductal papilloma]]
- <span style="background:rgba(240, 200, 0, 0.2)">BIoody [[nipple discharge|nipple discharge]] in pre-menopausal women (vs. Papillary Carcinoma)</span>
- <span style="background:rgba(240, 200, 0, 0.2)">FibrovascuIar projections lined by luminal myoepithelial cells (vs. Papillary Carcinoma)</span>

![[Pasted image 20241017174131.png|Pasted image 20241017174131.png]]
![[Pasted image 20241017174211.png|Pasted image 20241017174211.png]]

>[!Mnemonic] 
>- <font color="#ffc000">I</font>ntraductal = Myoepithelium <font color="#ffc000">I</font>ncluded
>- <font color="#ffc000">P</font>apillary = Myoepithelium <font color="#ffc000">P</font>opped

## Fibroadenoma
- Refers to a marble-like, rubbery mobile, stromal/glandular benign tumor
- <span style="background:rgba(240, 200, 0, 0.2)">Estrogen sensitive (will enlarge during pregnancy/menstrual cycle)</span>
- Typically occurs in 15-35 y/o women
- Biopsy: fibrous and glandular tissue![[Pasted image 20241018090342.png|Pasted image 20241018090342.png]]

>[!Mnemonic] 
>fib<font color="#ffc000">RO</font>adenoma = est<font color="#ffc000">RO</font>gen sensitive

## Phyllodes tumor
- Refers to a fibroepithelial tumor that ranges from benign (mostly) to malignant (rarely)
- <span style="background:rgba(240, 200, 0, 0.2)">Characteristic **leaf-like projections into epithelium-lined stroma & dilated lumen**</span>
- Typically occurs in **40-50 y/o women**

# Malignant cancer
---
![[Pasted image 20240416200003.png|Pasted image 20240416200003.png]]
## Noninvasive carcinomas
### Ductal carcinoma in situ (DCIS)
- Characteristics
	- <span style="background:rgba(240, 200, 0, 0.2)">No penetration of the basement membrane</span>
	- Preceded by ductal atypia
	- Frequently appears as a pattern of grouped <span style="background:rgba(240, 200, 0, 0.2)">microcalcifications</span> on mammography
	- Higher risk of subsequent ipsilateral invasive carcinoma
- Comedocarcinoma
	- Characteristics: subtype of DCIS characterized by central necrosis![[L67791.jpg|L67791.jpg]]

>[!tip] 
>Noninvasive carcinomas are characterized by the absence of stromal invasion.
### Lobular carcinoma in situ (LCIS)
- Refers to proliferation of lobular cells but has not yet invaded basement membrane
- <span style="background:rgba(240, 200, 0, 0.2)">Lacks E-Cadherin</span>

>[!Mnemonic] 
><font color="#ffc000">L</font>obular <font color="#ffc000">C</font>arcinoma <font color="#ffc000">L</font>acks <font color="#ffc000">C</font>adherin
## Invasive carcinomas
### Invasive ductal carcinoma (IDC)
- Characteristics
	- <span style="background:rgba(240, 200, 0, 0.2)">Most common type of invasive breast cancer (∼ 80%) </span>
	- Aggressive formation of metastases
- Localization
	- Unilateral
	- Mostly unifocal
#### Medullary breast cancer 
- Characteristics
	- Rare subtype of invasive ductal carcinoma
	- Most common tumor associated with the BRCA1 mutation
	- Well-circumscribed soft tumor with smooth borders (may appear benign)![[L67792.jpg|L67792.jpg]]
	- Usually triple-negative
	- Lymphadenopathy 
- Differential diagnosis: fibroadenoma
### Invasive lobular carcinoma (ILC) 
- Characteristics
	- <span style="background:rgba(240, 200, 0, 0.2)">∼ 10% of all invasive breast carcinomas</span>
	- Less aggressive than ductal carcinoma
	- Monomorphic cells in a <span style="background:rgba(240, 200, 0, 0.2)">single file pattern</span> due to a decrease in E-cadherin expression![[paste-225636106895941.jpg|paste-225636106895941.jpg]]
- Localization
	- <span style="background:rgba(240, 200, 0, 0.2)">Bilateral</span> in ∼ 20% of cases
	- <span style="background:rgba(240, 200, 0, 0.2)">Frequently multifocal</span>

>[!Mnemonic] 
><font color="#ffc000">ILC</font> = <font color="#ffc000">I</font>ndividual <font color="#ffc000">L</font>ine <font color="#ffc000">C</font>arcinoma
# Clinical features
---
## Locally advanced disease
- Skin
	- <span style="background:rgba(240, 200, 0, 0.2)">Retractions or dimpling</span> (due to fixation to the pectoral muscles, deep fascia, Cooper ligaments, and/or overlying skin)
	- Peau d'orange (see below)
# Subtypes and variants
---
## Inflammatory conditions (DDx)
- Mastitis
- [[Mammary duct ectasia|Mammary duct ectasia]]
- [[Fat necrosis of the breast|Fat necrosis of the breast]]
## Paget disease of the breast
- Definition: a rare type of breast cancer that <span style="background:rgba(240, 200, 0, 0.2)">affects the lactiferous ducts and the skin of the nipple and areola</span>
- Pathogenesis: migratory/epidermotropic theory: neoplastic ductal epithelial cells from an underlying DCIS or IDC  move through the lactiferous ducts and invade the surrounding epidermis of the nipple.
- Clinical features![[Pasted image 20240412145835.png|Pasted image 20240412145835.png]]
	- <span style="background:rgba(240, 200, 0, 0.2)">Erythematous, scaly, or vesicular rash affecting the nipple and areola</span>
	- <span style="background:rgba(240, 200, 0, 0.2)">Pruritus; burning sensation</span>
	- <span style="background:rgba(240, 200, 0, 0.2)">Nipple retraction</span>
	- Ulceration that causes blood-tinged [[nipple discharge|nipple discharge]]
- Diagnostics
	- Punch/wedge or surface biopsy of nipple tissue: <span style="background:rgba(240, 200, 0, 0.2)">Paget cells</span> confirm disease.![[Pasted image 20241010083736.png|Pasted image 20241010083736.png]]
## Inflammatory breast cancer (IBC)
- Definition: a rare form of advanced, aggressive invasive carcinoma <span style="background:rgba(240, 200, 0, 0.2)">characterized by dermal lymphatic invasion of tumor cells</span>
- Clinical features![[Pasted image 20240416202309.png|Pasted image 20240416202309.png]]
	- Peau d'orange
		- <span style="background:rgba(240, 200, 0, 0.2)">Erythematous, warm, and edematous skin plaques with prominent hair follicles that resemble orange peel</span>
		- Caused by <span style="background:rgba(240, 200, 0, 0.2)">obstruction of the lymphatic channels</span> due to tumor growth  
	- <span style="background:rgba(240, 200, 0, 0.2)">Tenderness</span>, burning sensation
	- Blood-tinged [[nipple discharge|nipple discharge]]
	- <span style="background:rgba(240, 200, 0, 0.2)">Signs of metastatic disease (e.g., axillary lymphadenopathy)</span> 
	- <span style="background:rgba(240, 200, 0, 0.2)">Usually no palpable mass</span>
- Differential diagnosis
	- <span style="background:rgba(240, 200, 0, 0.2)">Mastitis</span>
		- Fever
		- No Peau d'orange
		- Good response to antibiotics
	- Paget disease of the breast
	- Breast abscess

>[!tip] 
>It is called inflammatory breast cancer because its appearance resembles inflammation, but there is actually no inflammation!
# Diagnostics
---
## Receptor testing
![[Pasted image 20240311145001.png|Pasted image 20240311145001.png]]
- Hormone receptors (HR) positive
	- [[Androgen and estrogen synthesis|Estrogen]] receptor
	- Progestogen receptor
- Human epidermal growth factor receptor 2 (HER2/neu, c-erbB2) positive
- Triple negative
### Prognosis
- <span style="background:rgba(240, 200, 0, 0.2)">Hormone-negative breast cancer has a poorer prognosis than hormone-positive breast cancer. </span>
- <span style="background:rgba(240, 200, 0, 0.2)">HER2-positive tumors show aggressive growth and metastasize quickly compared to HER2-negative tumors. </span>
- <span style="background:rgba(240, 200, 0, 0.2)">Triple-negative disease is associated with a poor prognosis.</span>

# Treatment
---
## Systemic therapy
### ERBB2-targeted therapy <span style="background:rgba(240, 200, 0, 0.2)">(ERBB2 = HER2)</span>
ERBB2-targeted therapy includes <span style="background:rgba(240, 200, 0, 0.2)">ERBB2 antibodies (e.g., trastuzumab, pertuzumab) and tyrosine kinase inhibitors (e.g., lapatinib, neratinib).</span>
- Indication: all ERBB2+ tumors
- First-line agent: trastuzumab
	- A humanized monoclonal antibody against the ERBB2 tyrosine kinase receptor; used in the treatment of ERBB2+ breast and gastric cancer 
	- <span style="background:rgba(240, 200, 0, 0.2)">Mechanism of action: targets c-erbB2 tyrosine kinase receptor → ↓ of ERBB2-initiated cellular signaling and ↑ antibody-dependent cytotoxicity → ↓ tumor growth</span>
	- Adverse effects: cardiotoxicity (e.g., dilated cardiomyopathy with systolic CHF)
